Literature DB >> 22929983

Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Martin Schmidt-Hieber1, María Laura Gutiérrez, Martin Pérez-Andrés, Bruno Paiva, Ana Rasillo, Maria Dolores Tabernero, José Maria Sayagués, Antonio Lopez, Paloma Bárcena, María Luz Sanchez, Norma C Gutiérrez, Jesus F San Miguel, Alberto Orfao.   

Abstract

Cytogenetic studies in clonal plasma cell disorders have mainly been done in whole bone marrow or CD138(+) microbead-enriched plasma cells and suggest that recurrent immunoglobulin heavy chain translocations - e.g. t(4;14) -are primary oncogenetic events. The aim of this study was to determine cytogenetic patterns of highly purified aberrant plasma cells (median purity ≥ 98%) in different clonal plasma cell disorders. We analyzed aberrant plasma cells from 208 patients with multiple myeloma (n=148) and monoclonal gammopathy of undetermined significance (n=60) for the presence of del(13q14), del(17p13) and t(14q32) using multicolor interphase fluorescence in situ hybridization. Additionally, immunoglobulin heavy chain gene arrangements were analyzed and complementarity determining region 3 was sequenced in a subset of patients and combined multicolor interphase fluorescence in situ hybridization/immunofluorescent protein staining analyses were performed in selected cases to confirm clonality and cytogenetic findings. At diagnosis, 96% of cases with multiple myeloma versus 77% of monoclonal gammopathy of undetermined significance cases showed at least one cytogenetic alteration and/or hyperdiploidy. The cytogenetic heterogeneity of individual cases reflected coexistence of cytogenetically-defined aberrant plasma cell clones, and led to the assumption that karyotypic alterations were acquired stepwise. Cases of multiple myeloma and monoclonal gammopathy of undetermined significance frequently showed different but related cytogenetic profiles when other cytogenetic alterations such as deletions/gains of the immunoglobulin heavy chain or the fibroblast growth factor receptor 3 were additionally considered. Interestingly, in 24% of multiple myeloma versus 62% of monoclonal gammopathy of undetermined significance patients with an immunoglobulin heavy chain translocation, aberrant plasma cells with and without t(14q32) coexisted in the same patient. Our data suggest that recurrent immunoglobulin heavy chain translocations might be absent in the primordial plasma cell clone in a significant proportion of patients with clonal plasma cell disorders carrying these cytogenetic alterations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929983      PMCID: PMC3561437          DOI: 10.3324/haematol.2011.060632

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  35 in total

1.  Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.

Authors:  Sandra Quijano; Antonio López; Ana Rasillo; Susana Barrena; Maria Luz Sánchez; Juan Flores; Carlos Fernández; José María Sayagués; Carlos Salvador Osuna; Nuria Fernández; Marcos González; Pilar Giraldo; Manuel Giralt; Maria Carmen Pérez; José Manuel Martin-Antoran; Oliver Gutiérrez; Luis Perdiguer; Joaquín Díaz Mediavilla; Manuel González Silva; Agustín Asensio Del Rio; Carlos Cerveró; José Luis Guerra; Rosario Butrón; Maria del Carmen García; Julia Almeida; Alberto Orfao
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

2.  Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach.

Authors:  Wendy G Nieto; Julia Almeida; Alfonso Romero; Cristina Teodosio; Antonio López; Ana F Henriques; Maria Luz Sánchez; María Jara-Acevedo; Ana Rasillo; Marcos González; Paulino Fernández-Navarro; Tomás Vega; Alberto Orfao
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

3.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

4.  Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.

Authors:  Samantha Reid; S Yang; R Brown; K Kabani; E Aklilu; P J Ho; N Woodland; D Joshua
Journal:  Int J Lab Hematol       Date:  2010-12       Impact factor: 2.877

5.  Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Authors:  Kai Neben; Anna Jauch; Uta Bertsch; Christiane Heiss; Thomas Hielscher; Anja Seckinger; Tina Mors; Nadine Zoe Müller; Jens Hillengass; Marc S Raab; Anthony D Ho; Dirk Hose; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

Review 6.  Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.

Authors:  Bruno Paiva; Julia Almeida; Martin Pérez-Andrés; Gema Mateo; Antonio López; Ana Rasillo; María-Belén Vídriales; María-Consuelo López-Berges; Jesús F San Miguel; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2010-07       Impact factor: 3.058

7.  Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting.

Authors:  Jana Cumova; L Kovarova; A Potacova; I Buresova; F Kryukov; M Penka; J Michalek; R Hajek
Journal:  Int J Hematol       Date:  2010-08-07       Impact factor: 2.490

8.  Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia.

Authors:  Natalie Put; Heidi Lemmens; Iwona Wlodarska; Peter Konings; Yves Moreau; Anne Hagemeijer; Peter Vandenberghe; Lucienne Michaux
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

9.  The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Gema Mateo; Jose J Pérez; Maria Angeles Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de las Heras; Maria Victoria Mateos; Maria Consuelo López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Yolanda González; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San-Miguel
Journal:  Blood       Date:  2009-09-15       Impact factor: 22.113

Review 10.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

View more
  17 in total

1.  Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Authors:  Adrian A Carballo-Zarate; L Jeffrey Medeiros; Lianghua Fang; Jatin J Shah; Donna M Weber; Sheeba K Thomas; Elisabet E Manasanch; Suyang Hao; Qi Shen; Robert Z Orlowski; Pei Lin; Xinyan Lu
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

2.  Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.

Authors:  T Paíno; B Paiva; J M Sayagués; I Mota; T Carvalheiro; L A Corchete; I Aires-Mejía; J J Pérez; M L Sanchez; P Barcena; E M Ocio; L San-Segundo; M E Sarasquete; R García-Sanz; M-B Vidriales; A Oriol; M-T Hernández; M-A Echeveste; A Paiva; J Blade; J-J Lahuerta; A Orfao; M-V Mateos; N C Gutiérrez; J F San-Miguel
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

3.  In silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR.

Authors:  Dong Leng; Ran Miao; Xiaoxi Huang; Ying Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

4.  Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Leandro S Thiago; Martin Perez-Andres; Ana Balanzategui; Maria E Sarasquete; Bruno Paiva; Maria Jara-Acevedo; Paloma Barcena; Maria Luz Sanchez; Julia Almeida; Marcos González; Jesus F San Miguel; Ramón Garcia-Sanz; Alberto Orfao
Journal:  Haematologica       Date:  2013-07-19       Impact factor: 9.941

Review 5.  B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.

Authors:  José P Vaqué; Nerea Martínez; Ana Batlle-López; Cristina Pérez; Santiago Montes-Moreno; Margarita Sánchez-Beato; Miguel A Piris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 6.  Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

Authors:  Francesco Maura; Niccolò Bolli; Even H Rustad; Malin Hultcrantz; Nikhil Munshi; Ola Landgren
Journal:  JAMA Oncol       Date:  2020-03-01       Impact factor: 31.777

7.  Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.

Authors:  Jiangang Mei; Yongping Zhai; Hanqing Li; Feng Li; Xiaogang Zhou; Ping Song; Qian Zhao; Yaping Yu; Zhiming An; Liping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-24       Impact factor: 4.553

8.  Association between the cytogenetic profile of tumor cells and response to preoperative radiochemotherapy in locally advanced rectal cancer.

Authors:  María González-González; Jacinto Garcia; José A Alcazar; María L Gutiérrez; Luis M Gónzalez; Oscar Bengoechea; María M Abad; Angel Santos-Briz; Oscar Blanco; Manuela Martín; Ana Rodríguez; Manuel Fuentes; Luis Muñoz-Bellvis; Alberto Orfao; Jose M Sayagues
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

9.  Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Authors:  Charlotte Pawlyn; Lorenzo Melchor; Alex Murison; Christopher P Wardell; Annamaria Brioli; Eileen M Boyle; Martin F Kaiser; Brian A Walker; Dil B Begum; Nasrin B Dahir; Paula Proszek; Walter M Gregory; Mark T Drayson; Graham H Jackson; Fiona M Ross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2014-11-26       Impact factor: 25.476

Review 10.  Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms.

Authors:  Nadine Kutsch; Reinhard Marks; Richard Ratei; Thomas K Held; Martin Schmidt-Hieber
Journal:  Biomark Insights       Date:  2015-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.